Weekly Analysts’ Ratings Changes for Xencor (XNCR)

A number of firms have modified their ratings and price targets on shares of Xencor (NASDAQ: XNCR) recently:

• 9/30/2026 – Xencor is now covered by Wells Fargo & Company. They set an “overweight” rating and a $55.00 price target on the stock.
• 9/28/2026 – Xencor had its “buy” rating reaffirmed by Truist Financial Corporation. They now have a $29.00 price target on the stock, up from $27.00.
• 9/21/2026 – Xencor had its “sell (d-)” rating reaffirmed by Weiss Ratings.
• 9/21/2026 – Xencor had its price target raised by Bank of America Corporation from $20.00 to $26.00. They now have a “neutral” rating on the stock.
• 9/11/2026 – Xencor had its price target raised by Barclays PLC from $27.00 to $35.00. They now have an “overweight” rating on the stock.
• 9/3/2026 – Xencor had its price target raised by JPMorgan Chase & Co. from $14.00 to $21.00. They now have a “neutral” rating on the stock.
• 9/1/2026 – Xencor had its price target raised by Raymond James Financial, Inc. from $40.00 to $46.00. They now have a “strong-buy” rating on the stock.

Xencor, Inc is a clinical-stage biopharmaceutical company that develops engineered monoclonal antibodies and cytokine therapeutics for cancer, autoimmune diseases and other serious medical conditions. The company’s research is based largely on its XmAb technology platform, which is designed to modify antibody structures to improve immune-system activity, extend drug half-life or enable the simultaneous targeting of multiple biological pathways.

Xencor’s pipeline includes investigational therapies intended to engage immune cells, regulate immune responses and target tumor-associated proteins.